Protocol direction: full HPA shutdown (LH/FSH zero) → normalize the absurd metabolite marker → natural reboot…
u/drwillpowers
r/DrWillPowers2026-04-14T22:12:28Z
Dr Will Powers’ own statements and theorizing
Mentions treatments or doses — not guidance
Summary (paraphrased)
Replying to a commenter proposing HPTA shutdown followed by bypass hormones (Primobolan/E2/progesterone) to route around the UGT2B17 clearance defect, Powers describes his current protocol direction: shut the HPA axis fully off (LH/FSH to zero), then track the patient's absurd metabolite lab — e.g., unmeasurably high 3a-ADG in UGT2B17 cases — down to normalization, assess how the patient feels, then allow natural reboot and decide next steps (including HDAC drugs) from there. He frames washing the system out completely — potentially the inverse of the drug-induced state — as the candidate approach, while stressing it is off-label and experimental, with no approved treatment existing, and requiring volunteers who understand that. In the same comment set he discusses androgen-receptor overexpression as compensatory (accumulated weak-agonist metabolites acting like bicalutamide) and shares topical-testosterone dosing experience.
Key points (paraphrased)
- Protocol direction: full HPA shutdown (LH/FSH zero) → normalize the absurd metabolite marker → natural reboot → reassess.
- Metabolite normalization (patient-specific marker) as the recovery biomarker.
- AR overexpression interpreted as compensation for metabolite "noise" (bicalutamide analogy).
- Explicitly off-label and experimental; informed consent; no approved treatment exists.
- Topical testosterone dosing experience shared (0.1% gel context).
Why it’s in the corpus
The clearest description of his experimental treatment protocol and the metabolite-normalization biomarker concept. It also captures his ethical framing — informed consent for off-label experimentation when no approved path exists.
Context — the post Powers was replying toVerbatim third-party text, shown for context only — not Powers’ statement. Usernames removed.ShowHide
Powers' comment replies to [username removed], who proposed shutting down the HPTA, waiting for testosterone to clear, then adding bypass hormones to route around the UGT2B17 clearance bridge — noting they personally crash testosterone and get massive windows — in the "REPOST DUTCH test results" thread.
(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)
Some fields on this page come from the release’s Markdown edition, which carries text the JSON edition omits.
Related records
- Powers · Reddit commentCurated Powers pick
Re: The Problems with the Theory of Impaired Androgen Signaling caused by Metabolite Accumulation: A Peaceful Challenge to Dr. Powers’ Thesis
u/drwillpowers · r/DrWillPowers
Long reply to a community member's critique of his impaired-androgen-signaling theory. Powers concedes his earlier strong claim — that androgens must exit through DHT when UGTs are impaired — was overstated: testosterone can route through oxidation…
AKR1C3ARUGT2B17PRH-01172026-09-20T19:15:54ZPFSPowers Reddit history - Peer-reviewed paperPSSD Discord pick
Multiple roles for UDP-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes in androgen metabolism and prostate cancer evolution
Gauthier-Landry L, Bélanger A, Barbier O · Journal of Steroid Biochemistry and Molecular Biology
Review of two glucuronidation enzymes, UGT2B15 and UGT2B17, that convert DHT metabolites (3α-diol and androsterone) into inactive, easily excreted glucuronide conjugates. It describes how these enzymes control local androgen availability and androgen-receptor…
ARUGT2B15UGT2B17DISC-0032015 (epub 2014)PFSPSSD Discord picks - Peer-reviewed paperSIDEfxHUB pick
Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia
Cauci, Sabina; Chiriacò, Giovanni; Cecchin, Erika; Toffoli, Giuseppe; Xodo, Serena; Stinco, Giuseppe; Trombetta, Carlo · Sexual Medicine · 5(1):e61-e71
In 66 PFS patients, short/long (CAG)n and (GGN)n repeat lengths in the androgen receptor gene were associated with different symptom frequencies (libido loss, genital sensitivity changes, muscle tone, skin dryness, etc.), with a U-shaped pattern for some…
ARPFS-0072017PFSCore corpus